Recent advances in neoantigen research have accelerated the development and regulatory
approval of tumor immunotherapies, including cancer vaccines, adoptive cell therapy and …

Historically, cancer research and therapy have focused on malignant cells and their tumor
microenvironment. However, the vascular, lymphatic and nervous systems establish long …

Tumor microenvironment (TME) takes critical roles in tumor resistance to immune checkpoint
inhibitors (ICIs) including anti-programmed death-1 (PD-1) or anti-programmed death-ligand …

The clinical use of tumour-infiltrating lymphocytes for the treatment of solid tumours is
hindered by the need to obtain large and fresh tumour fractions, which is often not feasible in …

Neoantigen vaccines are based on epitopes of antigenic parts of mutant proteins expressed
in cancer cells. These highly immunogenic antigens may trigger the immune system to …

Circulating T cells from peripheral blood (PBL) can provide a rich and noninvasive source
for antitumor T cells. By single-cell transcriptomic profiling of 36 neoantigen-specific T cell …

Intra-tumoral immune cells promote the stemness of cancer stem cells (CSCs) in the tumor
microenvironment (TME). CSCs promote tumor progression, relapse, and resistance to …

Adoptive cell therapy using T cell receptor-engineered T cells (TCR-T) is a promising
approach for cancer therapy with an expectation of no significant side effects. In the human …

Resistance to immune checkpoint inhibitors (ICIs) is a major issue of the current era in
cancer immunotherapy. Immune evasion is a multi-factorial event, which occurs generally at …

Neoantigen immunogenicity prediction is a burgeoning field with vast potential; however, the
shortage of high-quality data and biases in current datasets limit model generalizability …